/Investor DB

Abingworth — 2021 Investments

5 investments dated 2021 · listed companies and verified rows first · show all

Allotera Therapeuticsalloteratx.comSeries B · Jul 2021 · $170M

Allotera develops allogeneic (off-the-shelf) CAR-T cell therapies targeting T-cell cancers such as T-cell acute lymphoblastic leukemia, T-cell lymphoblastic lymphoma, and T-cell non-Hodgkin's lymphoma, as well as autoimmune indications.

BiotechHealthtechSt. Louis, US

Board seatBali MuralidharNatalie Mount· per SEC Form D

Co-investorsAisling CapitalBioGenerator VenturesLYZZ CapitalRiverVest Venture Partners

Cymabaycymabay.comin𝕏Aug 2021 · $100M

Gilead Sciences is a biopharmaceutical company headquartered in Foster City, California that discovers, develops, and delivers medicines across virology, oncology, and inflammation.

BiotechHealthtechMedical DevicesNewark, US

Harold Van Wart, Ph. D.(Executive Officer, Director)Pol Boudes(Executive Officer)Charles A. McWherter, Ph. D.(Executive Officer)Sujal Shah(Executive Officer)

BoardCarl Goldfischer, M.D.(Director)Kurt von Emster(Director)in

Co-investorsAvoro Capital AdvisorsBay City CapitalForesite CapitalVantagePoint Capital Partners

ROME Therapeuticsrometx.comSep 2021

Boston-based biotech developing drugs against the 'dark genome'/repeatome for autoimmune disease, cancer and neurodegeneration.

Benjamin Greenbaum(Founder)David Ting(Founder)Rosana Kapeller(Founder)

Co-investorsAndreessen HorowitzARCH Venture PartnersGV (Google Ventures)Luma GroupSanofi VenturesAdvent Life Sciences+11 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Anjarium BiosciencesVera Therapeutics

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.